BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
JEMPERLI (dostarlimab) by GSK is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2021.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEMPERLI (dostarlimab) is a PD-1 blocking monoclonal antibody approved in April 2021 for treating cancers with specific molecular profiles. It works by unleashing the immune system to recognize and attack tumor cells by blocking the programmed death receptor-1 pathway. The drug is currently in peak commercial lifecycle, indicating strong market establishment.
$0.002BPart D
PeakPeak lifecycle positioning indicates mature market presence with established sales infrastructure; commercial teams are optimizing market penetration rather than building from launch.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
Started Sep 2026
90 enrolled
Neoplasms, Rectal
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer
Started Aug 2026
100 enrolled
Neoplasms, Endometrial
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
Started Jan 2026
270 enrolled
Locally Advanced Rectal Cancer (LARC)
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Started Nov 2025
30 enrolled
Neoplasms, Endometrial
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Started Oct 2025
25 enrolled
MMRd/MSI-H Stage II-III Endometrial Cancer
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.